Google
KZIA — KAZIA THERAPEUTICS LTD ADR (Healthcare >> Biotechnology)
KZIA FAQ
What is KZIA's ROE?
KAZIA THERAPEUTICS LTD ADR reports a Return on Equity (ROE) of -109.18%.
What is KZIA's dividend yield?
KAZIA THERAPEUTICS LTD ADR offers a dividend yield of 0.00%.
What is KZIA's Deepscope Quality Score?
Deepscope rates KZIA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KZIA?
Deepscope's AI Timing Score for KZIA is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KZIA belong to?
KAZIA THERAPEUTICS LTD ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 10.99
Price
-0.41
(-3.60%)
Day Change
|
|
|---|
KZIA, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 72 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 10.99 |
| PBV / Sector |
2.81 / 4.63
|
| Earning Per Share | -4.28 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
2.64 M
GREAT
|
| Average 1W Daily Value |
2.71 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:48 |
| Symbol | KZIA |
| Name | KAZIA THERAPEUTICS LTD ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 11.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 130.27 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Three International Towers, Sydney, NSW, Australia, 2000
Phone: 61 2 9472 4101
Website: https://www.kaziatherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
